Johnson & Johnson (JNJ) News Today

Johnson & Johnson (NYSE:JNJ) shares have pulled back today amid mixed news flow, with investor focus on recent analyst upgrades and pipeline progress offset by broader market pressure and reputational concerns tied to its spun‐off consumer unit.

• Positive Sentiment: Goldman Sachs raised its price target on JNJ to $186.00 and reiterated a “buy” rating, reflecting a projected upside of over 6% from current levels. The Goldman Sachs Group Raises Price Target to $186
• Positive Sentiment: Analyst commentary highlights J&J’s strong technical momentum and robust drug pipeline, which helped add approximately $63 billion in market cap over the past three months. J&J Adds $63B in Market Cap
• Positive Sentiment: JNJ announced the European launch of its Shockwave Javelin Peripheral IVL Catheter for treating peripheral artery disease, expanding its MedTech footprint. Shockwave Javelin Peripheral IVL Catheter Launch
• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion on nipocalimab for generalized myasthenia gravis, marking another late-stage win for J&J’s immunology portfolio. Positive CHMP Opinion for Nipocalimab
• Positive Sentiment: A recent analysis suggests a wave of FDA approvals is reshaping J&J’s innovation narrative, with multiple product green lights boosting confidence in its R&D engine. Wave of FDA Successes
• Neutral Sentiment: Goldman Sachs maintained its “buy” rating on J&J without changing its price target, underscoring steady analyst support. Goldman Sachs Keeps Buy Rating
• Neutral Sentiment: J&J is mentioned among potential long-term winners in a roundup of dividend aristocrats, though the article focuses on broad market trends rather than company‐specific catalysts. Dividend Kings Article
• Negative Sentiment: JNJ shares are trading down around 1.1% amid market-wide softness and profit-taking after recent gains. Trading Down 1.1%
• Negative Sentiment: Spinoff Kenvue faces renewed scrutiny after reports the U.S. administration may issue warnings about a potential Tylenol-autism link, raising reputational and regulatory concerns for both Kenvue and parent J&J. Tylenol-Autism Warning Plans